17% der Patienten unter Aprepitant-Therapieschema im Vergleich zu 13% der Patienten unter Standardtherapie berichtet, wobei die Patienten eine hoch emetogene Chemotherapie erhielten. ###>Adverse reactions considered as drug-related by the investigator were reported in approximately 17% of patients treated with the aprepitant regimen compared with approximately 13% of patients treated with standard therapy in patients receiving highly emetogenic chemotherapy.